Abstract

Support is requested to permit participation in the cooperative clinical trials of Cancer and Leukemia Group B which is dedicated to improving the treatment of cancer. UAB will participate in: Phase II non-randomized studies using historical controls or randomized studies using concurrent population controls, of the effectiveness of a specific treatment in a series of patients with specific cancers; Phase III randomized comparison of two or more treatment plans. Emphasis is placed on multi-modality programs and adjuvant treatment programs. The above studies are directed against adult cancers, including leukemias, lymphomas, breast cancer, lung cancer, and other solid tumors. The various modalities being developed and tested include surgery, radiotherapy, cytotoxic drugs and biologic response modifiers. Pathology review will be stressed. In addition to Group studies as described, ancillary studies are encouraged. Thorough planning, careful review of data, and statistically sound evaluation of results are essential components. Important secondary benefits of these studies are the excellence of patient care and improved training of medical students, house officers and fellows which ensue.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA047545-03
Application #
3558778
Study Section
Cancer Clinical Investigation Review Committee (CCI)
Project Start
1988-04-01
Project End
1993-03-31
Budget Start
1990-04-20
Budget End
1991-03-31
Support Year
3
Fiscal Year
1990
Total Cost
Indirect Cost

  Institution

Name
University of Alabama Birmingham
Department
Type
Schools of Medicine
DUNS #
004514360
City
Birmingham
State
AL
Country
United States
Zip Code
35294

  Publications

Lichtman, S M; Hurria, A; Cirrincione, C T et al. (2012) Paclitaxel efficacy and toxicity in older women with metastatic breast cancer: combined analysis of CALGB 9342 and 9840. Ann Oncol 23:632-8
Farag, Sherif S; Maharry, Kati; Zhang, Mei-Jie et al. (2011) Comparison of reduced-intensity hematopoietic cell transplantation with chemotherapy in patients age 60-70 years with acute myelogenous leukemia in first remission. Biol Blood Marrow Transplant 17:1796-803
Smith, S M; Johnson, J; Cheson, B D et al. (2009) Recombinant interferon-alpha2b added to oral cyclophosphamide either as induction or maintenance in treatment-naive follicular lymphoma: final analysis of CALGB 8691. Leuk Lymphoma 50:1606-17
Bogart, Jeffrey A; Watson, Dorothy; McClay, Edward F et al. (2008) Interruptions of once-daily thoracic radiotherapy do not correlate with outcomes in limited stage small cell lung cancer: analysis of CALGB phase III trial 9235. Lung Cancer 62:92-8
Mrozek, Krzysztof; Carroll, Andrew J; Maharry, Kati et al. (2008) Central review of cytogenetics is necessary for cooperative group correlative and clinical studies of adult acute leukemia: the Cancer and Leukemia Group B experience. Int J Oncol 33:239-44
Cancer and Leukemia Group B 8461; Farag, Sherif S; Archer, Kellie J et al. (2006) Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461. Blood 108:63-73
Silverman, Lewis R; McKenzie, David R; Peterson, Bercedis L et al. (2006) Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol 24:3895-903
Lamont, Elizabeth B; Herndon 2nd, James E; Weeks, Jane C et al. (2006) Measuring disease-free survival and cancer relapse using Medicare claims from CALGB breast cancer trial participants (companion to 9344). J Natl Cancer Inst 98:1335-8
Halabi, Susan; Vogelzang, Nicholas J; Ou, San-San et al. (2006) Clinical outcomes by age in men with hormone refractory prostate cancer: a pooled analysis of 8 Cancer and Leukemia Group B (CALGB) studies. J Urol 176:81-6
Paschka, Peter; Marcucci, Guido; Ruppert, Amy S et al. (2006) Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study. J Clin Oncol 24:3904-11

Showing the most recent 10 out of 36 publications